Home  >  News
Msc_Apr23 Advertisement
you can get e-magazine links on WhatsApp. Click here
Corporate + Font Resize -

Akums Drugs receives license to manufacture LDL-cholesterol drug bempedoic acid

Our Bureau, New Delhi
Monday, May 23, 2022, 16:30 Hrs  [IST]

Contract manufacturing pharma player Akums Drugs & Pharmaceuticals Ltd announced that it has received the license to manufacture and commercialise bempedoic acid, a novel, oral non-statin lipid-lowering treatment option. Bempedoic acid is a new class of drug for treating high LDL-cholesterol conditions.
It said that the bempedoic acid is known to be low risk for patients with intolerability for statins and is an important ingredient in most lipid-lowering drugs.
Over 272 out of every lakh of people have heart disease and with every fourth death in India is caused by heart alignment. Of these, some patients may also be intolerant to statins while others may already be prescribed the maximum dose they can tolerate in the course of their treatment. For such patients, bempedoic acid will be a great alternative for doctors.
Sandeep Jain, founder, promoter and director, Akums Drugs & Pharmaceuticals, said that as per statistics, there’re 112 million Indian adults suffer from high levels of LDL-cholesterol, out of this significantly high number of dyslipidaemic patients, who are already on statin-based treatments still continue to suffer from uncontrolled dyslipidaemia—for such patients, bempedoic acid is a fresh ray of hope.
"Our research & development teams are working on various combinations of bempedoic plus other molecules and soon these innovative products will also be introduced in India,” he added.
The therapy is an important addition to the management of dyslipidaemia through effective disease management. Bempedoic acid has shown positive results in supporting therapy in patients unable to tolerate or unresponsive to statins, which accounts for about 5.4 million Indian patients. This puts the drug in a class of its own, with the ability to do something that was till now unthinkable.
"At Akums Drugs, we are glad to be a part of such path-breaking initiatives and hope that together with our customers in pharmaceuticals, we will capture significant market share and be the pioneers in introducing the complete range of bempedoic acid,” he added.
Akums Drugs is a major contract manufacturer currently producing more than 12% of the country’s total medicinal requirements. The organisation deals in the manufacturing and export of formulations in a wide spectrum of dosage forms & therapeutic segments. The company is currently supplying to almost all Indian and multinational pharmaceutical companies across the globe and is the 67th largest employer of the country. The 10 state-of-the-art facilities are dedicated to oral solid dosage forms (with separate units for beta lactum and non-beta lactum formulations), Oral liquid dosage forms, Sterile dosage forms (injectable, eye, ear & nasal), hormonal (oral and injectable), ointments & cosmetics, ayurvedic, food supplements & nutraceuticals and animal health care.


* Name :     
* Email :    
  Website :  
Copyright © 2016 Saffron Media Pvt. Ltd |